The U.S. FDA has paused Moderna’s late-stage trial of its norovirus vaccine due to a case of Guillain-Barre syndrome, causing a clinical hold on the experimental mRNA-1403 vaccine. Meanwhile, Citadel has taken a short position worth 305 million pounds in British drugmaker GSK, as reported by the Financial Times.
About the Author
